Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2013) 122 (21): 3078.

https://doi.org/10.1182/blood.V122.21.3078.3078

Published: 2013

Journal Articles

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 2282.

https://doi.org/10.1182/blood.V122.21.2282.2282

Published: 2013

Journal Articles

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

Edmund A. Rossi, David M. Goldenberg, Rosana Michel, Diane L. Rossi, Daniel J. Wallace, Chien-Hsing Chang

Blood (2013) 122 (17): 3020–3029.

https://doi.org/10.1182/blood-2012-12-473744

Published: 2013

Includes: Supplemental data

Journal Articles

CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Daniel J Wallace, MD, Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 1357.

https://doi.org/10.1182/blood.V120.21.1357.1357

Published: 2012

Journal Articles

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2762.

https://doi.org/10.1182/blood.V120.21.2762.2762

Published: 2012

Journal Articles

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2451.

https://doi.org/10.1182/blood.V120.21.2451.2451

Published: 2012

Journal Articles

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien-Hsing Chang

Blood (2012) 119 (16): 3767–3778.

https://doi.org/10.1182/blood-2011-09-381988

Published: 2012

Includes: Supplemental data

Journal Articles

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Edmund A Rossi, Ph.D, Thomas M. Cardillo, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Richard R. Furman, MD, Chien-Hsing Chang, Ph.D

Blood (2011) 118 (21): 599.

https://doi.org/10.1182/blood.V118.21.599.599

Published: 2011

Journal Articles

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Rhona Stein, David M. Goldenberg, Chien-Hsing Chang

Blood (2011) 118 (7): 1877–1884.

https://doi.org/10.1182/blood-2011-03-343145

Published: 2011

Includes: Supplemental data

Journal Articles

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Chien-Hsing Chang

Blood (2010) 116 (17): 3258–3267.

https://doi.org/10.1182/blood-2010-03-276857

Published: 2010

Journal Articles

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Diane L Nordstrom, Edmund A Rossi, PhD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 1695.

https://doi.org/10.1182/blood.V114.22.1695.1695

Published: 2009

Journal Articles

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

Edmund A Rossi, PhD, Eric Chan, Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 3721.

https://doi.org/10.1182/blood.V114.22.3721.3721

Published: 2009

Journal Articles

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 114 (18): 3864–3871.

https://doi.org/10.1182/blood-2009-06-228890

Published: 2009

Includes: Supplemental data

Journal Articles

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 113 (24): 6161–6171.

https://doi.org/10.1182/blood-2008-10-187138

Published: 2009

Includes: Supplemental data

Journal Articles

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Thomas M. Cardillo, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Hans J. Hansen, Chien-Hsing Chang

Blood (2009) 113 (5): 1062–1070.

https://doi.org/10.1182/blood-2008-07-168146

Published: 2009

Includes: Supplemental data

Journal Articles

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Diane L Nordstrom, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1590.

https://doi.org/10.1182/blood.V112.11.1590.1590

Published: 2008

Journal Articles

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Rhona Stein, PhD, Diana Pilas, Diane L Nordstrom, John Kopinski, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1591.

https://doi.org/10.1182/blood.V112.11.1591.1591

Published: 2008

Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1588.

https://doi.org/10.1182/blood.V112.11.1588.1588

Published: 2008

Journal Articles

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Edmund A. Rossi, PhD, William J. McBride, Ph.D., Diane L. Nordstrom, M.S., Preeti Trisal, M.S., Thomas M. Cardillo, Ph.D., David M. Goldenberg, M.D. Sc.D., Chien-Hsing Chang, Ph.D.

Blood (2007) 110 (11): 1396.

https://doi.org/10.1182/blood.V110.11.1396.1396

Published: 2007

Journal Articles

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

David M. Goldenberg, ScD, MD, Robert M. Sharkey, PhD, Habibe Karacay, PhD, Chien-Hsing Chang, PhD, Edmund A. Rossi, PhD, William J. McBride, PhD

Blood (2007) 110 (11): 2344.

https://doi.org/10.1182/blood.V110.11.2344.2344

Published: 2007

NARROW

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only